Acetazolamide NDC 50090-5945

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-5945Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-5945Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-5945-0	50090594500	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (50090-5945-0)Marketed from Mar 23, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acetazolamide
Generic name (nonproprietary): acetazolamide
Active ingredients: Acetazolamide — 500 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040904
Marketing start: Feb 15, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
Identifiers: Product ID 50090-5945_acc7ad78-6382-40e2-a9f2-6344f04648ccSPL ID acc7ad78-6382-40e2-a9f2-6344f04648ccSPL set ID c5acf531-ba55-47b7-88db-e5da0206ebf1RxCUI 562524UNII O3FX965V0I
Pharmacologic class: Carbonic Anhydrase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090594500 followed by a unit qualifier and the quantity

Package 50090-5945-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 22, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE: For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide extended-release capsules are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040904

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040904
Product	Strength	Form · route	Labeler	Product NDC
Acetazolamide	Acetazolamide 500 mg/1	Capsule, Extended releaseOral	REMEDYREPACK INC.	70518-4646
Acetazolamide	Acetazolamide 500 mg/1	Capsule, Extended releaseOral	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-787
Acetazolamide	Acetazolamide 500 mg/1	Capsule, Extended releaseOral	Chartwell RX, LLC	62135-612